首页> 美国卫生研究院文献>other >Evaluation of Nine Somatic Variant Callers for Detection of Somatic Mutations in Exome and Targeted Deep Sequencing Data
【2h】

Evaluation of Nine Somatic Variant Callers for Detection of Somatic Mutations in Exome and Targeted Deep Sequencing Data

机译:评估九个体细胞变异调用者以检测外显子组和目标深度测序数据中的体细胞突变

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Next generation sequencing is extensively applied to catalogue somatic mutations in cancer, in research settings and increasingly in clinical settings for molecular diagnostics, guiding therapy decisions. Somatic variant callers perform paired comparisons of sequencing data from cancer tissue and matched normal tissue in order to detect somatic mutations. The advent of many new somatic variant callers creates a need for comparison and validation of the tools, as no de facto standard for detection of somatic mutations exists and only limited comparisons have been reported. We have performed a comprehensive evaluation using exome sequencing and targeted deep sequencing data of paired tumor-normal samples from five breast cancer patients to evaluate the performance of nine publicly available somatic variant callers: EBCall, Mutect, Seurat, Shimmer, Indelocator, Somatic Sniper, Strelka, VarScan 2 and Virmid for the detection of single nucleotide mutations and small deletions and insertions. We report a large variation in the number of calls from the nine somatic variant callers on the same sequencing data and highly variable agreement. Sequencing depth had markedly diverse impact on individual callers, as for some callers, increased sequencing depth highly improved sensitivity. For SNV calling, we report EBCall, Mutect, Virmid and Strelka to be the most reliable somatic variant callers for both exome sequencing and targeted deep sequencing. For indel calling, EBCall is superior due to high sensitivity and robustness to changes in sequencing depths.
机译:下一代测序已广泛应用于在癌症中,研究环境中以及越来越多的临床环境中对体细胞突变进行分类,以进行分子诊断,指导治疗决策。体细胞变异调用者对来自癌症组织和匹配的正常组织的测序数据进行配对比较,以检测体细胞突变。由于不存在检测体细胞突变的事实上的标准,并且仅报道了有限的比较,因此许多新的体细胞变异调用者的出现产生了对工具进行比较和验证的需求。我们已使用外显子组测序和目标深度测序数据对来自五名乳腺癌患者的配对肿瘤正常样品进行了全面评估,以评估九种公众可获得的体细胞变异调用者的性能:EBCall,Mutect,Seurat,Shimmer,Indelocator,Somatic Sniper, Strelka,VarScan 2和Virmid用于检测单核苷酸突变以及小的缺失和插入。我们报告说,在相同的测序数据和高度可变的协议下,来自九个体细胞变异调用者的调用数量存在很大差异。测序深度对单个呼叫者有明显不同的影响,对于某些呼叫者,增加测序深度可大大提高灵敏度。对于SNV调用,我们报告EBCall,Mutect,Virmid和Strelka是外显子组测序和靶向深度测序最可靠的体细胞变异调用者。对于indel调用,由于对测序深度的变化具有很高的灵敏度和鲁棒性,因此EBCall更具优势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号